

## Horizon 2020 continues to invest in CombiGene's epilepsy project

With the third payment from Horizon 2020, the EU program has so far invested EUR 2.85 million out of a total of EUR 3.36 million on CombiGene's epilepsy project CG01

On 15 May 2018, CombiGene announced that Horizon 2020 – EU's Framework Programme for Research and Development – is investing EUR 3.36 million in CombiGene's continued development and commercialisation of the gene therapy project CG01, which is developed to treat drug-resistant focal epilepsy.

The Horizon 2020 program runs for several years, and the initial payment amounted to EUR 1,51 million. The second payment, made in November 2019, amounted to EUR 1.21 million.

After careful review of the CG01 project by the EU and their external auditors, CombiGene has today received a third payment of EUR 130,000.

In total, CombiGene has received 85 percent of the total grant. CombiGene expects to receive an additional one to two payments before the total amount of EUR 3,36 million has been reached.



*"The payment from Horizon 2020 is further confirmation of the progress made in the CG01 project, not least the work we are carrying out to develop a commercially viable and future-proof production method," says Karin Agerman, Chief Research and Development Officer at CombiGene.*

*"In addition to having our project report approved and the money paid out, we have also received positive feedback and valuable recommendations from Horizon 2020's external reviewers. The fact that our epilepsy project is one of the projects that Horizon 2020 has chosen to invest in means a lot to CombiGene. In addition to the capital provided to the project, it is also a significant seal of quality on our development work and our commercial opportunities."*



CombiGene's lead project CG01 has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 823282

### About CombiGene AB

CombiGene's vision is to offer patients affected by severe life-changing diseases opportunities for a better life through innovative gene therapies. CombiGene's business concept is to develop effective gene therapies for serious diseases that today lack adequate treatment methods. Research assets are taken in from a network of external researchers and developed further up to clinical concept verification. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while CombiGene may drive the development and commercialization in-house for medicines aimed at limited patient populations. The company is public and listed on the Nasdaq First North Growth Market and the company's Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99, [info@fnca.se](mailto:info@fnca.se).

### For further information:

CombiGene AB (publ)  
Jan Nilsson, CEO  
Tel: +46 (0)704 66 31 63  
[jan.nilsson@combigene.com](mailto:jan.nilsson@combigene.com)

Bert Junno, Chairman of the board  
Tel: +46(0) 70 777 22 09  
[bert.junno@combigene.com](mailto:bert.junno@combigene.com)

**Please read *INGENIEIOUS*, a newsletter from CombiGene which contains general news and information that is judged not to have a significant effect on the share price. *INGENIEIOUS* and press releases are available at [www.combigene.com](http://www.combigene.com)**